Abstract
The efficacy of bisphosphonate in controlling skeletally-related event in cancer patients without a great number of adverse events has resulted in a widespread use of these medications in oncology. Zoledronic acid and pamidronate are the most common bisphosphonates intravenously administered as a preventive treatment of bone complications encountered in multiple myeloma, as well as a palliative treatment of bone metastases in a large variety of solid tumours including breast, prostate and lung cancers. However, in recent years a relationship has been established between these drugs and a new bone injury characterised by avascular necrosis of bone that was isolated to the jaws. This paper reviews the literature concerning the discovery of this disease, its clinical, radiological and histological manifestations; its pathogenesis, with a look at the treatment and future options in preventing this complication and in treating hypercalcemia and bone lytic lesions in solid tumours.
Lingua originale | English |
---|---|
pagine (da-a) | 115-121 |
Numero di pagine | 7 |
Rivista | JOURNAL OF BIOLOGICAL REGULATORS & HOMEOSTATIC AGENTS |
Volume | 24 |
Stato di pubblicazione | Pubblicato - 2010 |
Keywords
- Antineoplastic Agents
- Bone Neoplasms
- Diphosphonates
- Humans
- Jaw Diseases
- Lung Neoplasms
- Multiple Myeloma
- Osteonecrosis